Serum Institute of India
| File:Serum Institute of India logo.svg | |
| Founded | 1966  |
|---|---|
| Founder | Cyrus S. Poonawalla |
| Headquarters | Pune, India |
Key people | Adar Poonawalla (President) |
| Revenue |  US$595 million (2015) |
| US$295 million (2015) | |
Serum Institute of India is a manufacturer of immunobiological drugs including vaccines in India.[1][2] It was founded by Cyrus Poonawalla in 1966.[3]
The company is the world's largest vaccine producer by number of doses produced.[4] It is currently developing an intra-nasal swine flu vaccine.[5] In 2016, with support from US-based Mass Biologics of the University of Massachusetts Medical School, it invented a fast-acting anti-rabies agent, Rabies Human Monoclonal Antibody (RMAb), also known as Rabishield.[6]
In Mrach 2019, the company started developing COVID-19 vaccine for some strains of COVID-19 virus.[7]
References
- ^ "Serum Institute of India Pvt. Ltd.: Private Company Information". bloomberg.com. Retrieved 30 September 2018.
- ^ "SERUM INSTITUTE OF INDIA PRIVATE LIMITED - Company, directors and contact details". zaubacorp.com. Retrieved 30 September 2018.
- ^ "About Us". Serum Institute of India. Retrieved 8 December 2016.
- ^ "Cyrus Poonawalla on Forbes Lists". Forbes. Retrieved 24 March 2015.
- ^ "'India developing indigenous swine flu vaccine'". The Times of India. Retrieved 1 February 2015.
- ^ "Fast-acting anti-rabies drug set for India launch - Times of India". The Times of India. Retrieved 12 June 2016.
- ^ "Coronavirus vaccine within a year but it won't be 100% effective". The Economic Times. 23 March 2020. Retrieved 23 March 2020.
External links
  | This article about an Indian company is a stub. You can help Wikipedia by expanding it. |